Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Avista Public Acquisition Corp. II Market Cap
From what 0 stock analysts predict, the share price for Avista Public Acquisition Corp. II (AHPA) might decrease by 100% in the next year. This is based on a 12-month average estimation for AHPA. Price targets go from $ to $. The majority of stock analysts believe AHPA is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedAHPA 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Avista Public Acquisition Corp. II to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AHPA. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AHPA.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
When did it IPO
2017
Staff Count
0
Country
United States
Sector/Industry
/
CEO
Market Cap
$89.9M
In 2023, AHPA generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AHPA's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 01 Nov 2022
Sentiment - NEUTRAL
Source - Business Wire
Summary - No relevant financial information was provided in the news excerpt regarding Emeryville, California. Please provide additional details for a summary.
Why It Matters - Location announcements can signal business expansion or investment opportunities, affecting local economies and stock valuations. Investors may monitor developments in Emeryville for potential impacts.
Wed, 26 Oct 2022
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ligand announced that Janssen has received U.S. FDA approval for TECVAYLI™ (teclistamab), which may impact Ligand's market position and investor interest.
Why It Matters - FDA approval of TECVAYLI™ opens new revenue streams for Ligand, potentially boosting stock performance and attracting investor interest in biotech growth prospects.
Mon, 24 Oct 2022
Sentiment - NEUTRAL
Source - Business Wire
Summary - OmniAb's business combination has been approved by APAC shareholders, indicating a significant step forward for the company.
Why It Matters - The approval of the OmniAb business combination by APAC shareholders signals a significant corporate development, potentially affecting stock performance and market confidence.
Mon, 03 Oct 2022
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Avista Public Acquisition Corp. II (APAC) will hold a special meeting on October 24, 2022, to vote on its business combination with OmniAb, following SEC registration approval.
Why It Matters - The upcoming vote on the business combination between APAC and OmniAb could significantly impact share prices and market sentiment, influencing investment decisions in both companies.
Mon, 03 Oct 2022
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ligand Pharmaceuticals has announced the record date and details for the distribution related to the spin-off of its OmniAb unit.
Why It Matters - Ligand's spin-off of OmniAb may enhance shareholder value by unlocking potential in a focused entity, impacting stock performance and investment strategies.
Mon, 08 Aug 2022
Sentiment - NEUTRAL
Source - Business Wire
Summary - Ligand Pharmaceuticals has released its financial results for the second quarter of 2022. Further details are available in the full earnings report.
Why It Matters - Ligand's Q2 2022 financial results can impact stock performance, indicating company growth or challenges, influencing investor sentiment and potential future investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
